Renalytix secures contract with major US health insurance provider to boost coverage for kidney function test
KidneyIntelX™ is a test that helps predict if adults with type 2 diabetes and early-stage kidney problems are at risk of rapidly progressive decline in kidney function.
BlueCross and BlueShield Texas works with over 140,000 healthcare providers and 520 hospitals. This partnership adds to existing coverage from other Blues plans including Wellmark in Iowa and South Dakota ( 2.1 million covered lives), BlueCross BlueShield of Illinois (8.1 million covered lives), and CareFirst (3.4 million covered lives).
In addition, Renalytix has secured a contract with Parkland Community Health Plan, a Dallas based insurance plan with over 300,000 covered lives and service in seven counties, for insurance coverage of KidneyIntelX.
View from Vox
Securing coverage from these major statewide plans marks a key step in making KidneyIntelX™ available to a large population of adults suffering from type 2 diabetes and early-stage kidney disease.
KidneyIntelX™ splits patients into three risk levels - low, moderate, and high - which then provides clinicians with information on patient risk for progressive decline in kidney function within five years.
Over 37 million Americans (approximately 1 in 10) have diabetes, with about 90-95% of them having type 2 diabetes. Demand for KidneyIntelX™ is augmented by the fact that many people remain undiagnosed, with approximately 23% of adults unaware they have type 2 diabetes. Furthermore, type 2 diabetes affects various vital organs such as the heart, blood vessels, nerves, eyes, and kidneys, with diabetic kidney disease developing in 30-50% of individuals with type 2 diabetes.
KidneyIntelX™ is underpinned by Renalytix’s KidneyIntelX platform, which combines blood-based biomarkers with clinical variables using an AI-enabled algorithm, providing information to guide care in large, at-risk patient populations.
Overall, Renalytix's KidneyIntelX™ test should help to provide a solution to kidney disease management by assessing the risk and progression of kidney disease in patients with type 2 diabetes.
Follow Renalytix for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.